ClinicalTrials.gg
CompletedNCT06132256Updated Nov 16, 2026

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of Axatilimab and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Syndax Pharmaceuticals. Completed at 78 sites in 13 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Syndax Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Idiopathic Pulmonary Fibrosis with a site in Spain — 10 open to participants now, 16 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Spain.

Enrollment
37th of 54
145 · median 170
Started
2023
with 5 others
Phase 2
29 of 58
6 open now
Registered
40th of 58
by date

Among the 58 studies in Idiopathic Pulmonary Fibrosis with a site in Spain, this one is the 37th largest by enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2023, is one of 29 in phase 2, and was the 40th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

10 of the 58 studies in Idiopathic Pulmonary Fibrosis with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Idiopathic Pulmonary Fibrosis with a site in Spain, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of IPF per the 2018 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society Clinical Practice Guideline (Raghu 2018).
  • Chest high-resolution computed tomography (HRCT) performed within 12 months prior to first Screening Visit and according to the minimum requirements for IPF diagnosis by central review based on participant's HRCT only (if no lung is available) or based on both HRCT and lung biopsy (with application of the different criteria in either situation). If an evaluable HRCT \<12 months prior to Screening is not available, an HRCT can be performed at first Screening Visit to determine eligibility, according to the same requirements as the historical HRCT. If a participant has an indeterminate usual interstitial pneumonia (UIP) pattern and their HRCT is >6 months old, if in the opinion of the Investigator their disease has progressed, an additional HRCT may be obtained and reviewed for eligibility.
  • FVC ≥45% of predicted normal at Screening Visits.
  • (FEV1)/FVC ≥0.7 at Screening Visits.
  • DLco ≥30% and ≤90% of predicted, corrected for at first Screening Visit.

Key Exclusion Criteria:

  • Abnormalities detected on (ECG) of either rhythm or conduction that in the opinion of the Investigator are clinical significant. Participants with implantable cardiovascular devices (for example, pacemaker) affecting the time may be enrolled in the study based upon Investigator judgment following cardiologist consultation if deemed necessary, and only after discussion with the Medical Monitor.
  • Emphysema present on ≥50% of the HRCT, or the extent of emphysema is greater than the extent of fibrosis, according to central review of the HRCT.
  • Interstitial lung disease associated with known primary diseases (for example, connective tissue disease, sarcoidosis and amyloidosis), exposures (for example, radiation, silica, asbestos, and coal dust), or drugs (for example, amiodarone).
  • Participants who cannot meet protocol-specified baseline stability criteria.
  • Acute IPF exacerbation within 3 months prior to screening.
  • Receiving nintedanib in combination with pirfenidone
  • Receiving systemic equivalent to prednisone >10 milligrams (mg)/day or equivalent within 2 weeks prior to Screening.
  • Use of any of the following therapies within 4 weeks prior to Screening and during the Screening Period, or planned during the study: imatinib, ambrisentan, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine A, tacrolimus, bosentan, methotrexate, inhaled treprostinil, phosphodiesterase-5 inhibitors, including sildenafil (unless for occasional use), prednisone at steady dose >10 mg/day or equivalent, or other therapy.
  • History of cigarette smoking or vaping within the previous 3 months.
  • Female participant who is pregnant or breastfeeding.
  • Previous exposure to study intervention or known allergy/sensitivity to study drug.
  • Receiving an investigational treatment within 28 days of randomization.
  • Inadequate IV access.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Axatilimab

    Participants will receive axatilimab every 2 weeks during the 26-week Treatment Period.

    Drug: Axatilimab

  • Placebo comparator
    Placebo

    Participants will receive placebo every 2 weeks during the 26-week Treatment Period.

    Other: Placebo

Interventions

  • Administered as intravenous (IV) infusion

    Also known as: Niktimvo, SNDX-6352

  • OtherPlacebo

    Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.

06

What researchers measure

Primary outcomes

  1. Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])

    Time frame: Baseline through Week 26

Secondary outcomes

  1. Time to disease progression

    Disease progression is defined as absolute FVC percent predicted decline of ≥10%, or occurrence of lung transplant or all-cause death prior to Week 26.

    Time frame: Baseline through Week 26

  2. Annualized rate of decline in FVC percent predicted over 26 weeks

    Time frame: Baseline through Week 26

  3. Change in St. George's Respiratory Questionnaire (SGRQ) score from Baseline to Week 26

    Time frame: Baseline, Week 26

  4. Change in diffusion capacity for carbon monoxide (DLco % of predicted, corrected for hemoglobin) from Baseline to Week 26

    Time frame: Baseline, Week 26

07

Study locations

78 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Aug 2026, 32 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 32 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2026 → Aug 2026 and completion Nov 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 15, 2023
StartActual
Dec 11, 2023
Primary completionActual
Aug 27, 2026was Sep 2026
CompletionActual
Sep 10, 2026was Nov 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Sep 2026→Aug 27, 2026 (actual)
Nov 16, 2026
Study completion
Nov 2026→Sep 10, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Sep 2026→Aug 27, 2026 (now actual)
    Study completion Nov 2026→Sep 10, 2026 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06132256
Collaborators
DevPro Biopharma
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Dec 11, 2023
Primary completion
Aug 27, 2026
Completion
Sep 10, 2026
Last update
Nov 16, 2026

Study contacts

Medical Director
study director · Syndax Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion